Camel Research of Selected Pharmaceutical Industries
Shipra Gupta1, Vijay Kumar2, Jasmeet Kalra3
1Shipra Gupta, Assistant Professor, Department of Commerce, Graphic Era Hill University, (Uttarakhand), India.
2Vijay Kumar, Professor, Department of Physics, Graphic Era Hill University, (Uttarakhand), India.
3Jasmeet Kalra, Assistant Professor, Department of Mechanical Engineering, Graphic Era Hill University, (Uttarakhand), India.
Manuscript received on 27 April 2019 | Revised Manuscript received on 09 May 2019 | Manuscript Published on 18 May 2019 | PP: 9-18 | Volume-8 Issue-6S4 November 2019 | Retrieval Number: F10081186S419/19©BEIESP | DOI: 10.35940/ijeat.F1008.1186S419
Open Access | Editorial and Publishing Policies | Cite | Mendeley | Indexing and Abstracting
© The Authors. Blue Eyes Intelligence Engineering and Sciences Publication (BEIESP). This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Abstract: The pharmaceutical industry is observed to have an unhampered growth and is anticipated to grow supplemental a compound annual growth rate (CAGR) of 3-6% over the next five years. The worldwide expenditure on medicines has crossed US $1.2 Trillion in 2018 and is expected to go over US $ 1.5 Trillion by 2023. The new product lift-offs, particularly the specialty range have been the major contributor in the growth accomplishment. However, reforming per capita income, accelerating consciousness towards health, geriatric population, elevated chronic ailments along with technological magnifications are significantly pitching towards the growth accomplishment. The following economies have majorly pitched in towards the pharmaceuticals expenditure in 2018: US (US $ 486 Billion), top five European markets (US $ 178 Billion), China (US $ 137 Billion), Japan (US $ 86 Billion).Looking at the trend it seems that the growth of the world-wide pharmaceutical expenditure will majorly be moved by developed economies through innovatory products created using latest technology. United States appears to remain a fairy godmother in the pharmaceutical industry. However, emerging economies like Brazil, India, Russia (Tier 2 markets) and Tier 3 markets shall also confer to the growth process. Their CAGR is projected to grow 5-8% through 2023 to reach US $ 355 – 385 Billion.
Keywords: Pharmaceutical Industries, Capital Adequacy, Asset Quality, Management Efficiency, Earning Quality, Liquidity Position, Ratios, Performance.
Scope of the Article: Industrial Engineering